Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Case report

Treatment of colon cancer in a patient with systemic lupus erythematosus: a case report

Authors: Junfeng Shi, Jianquan Fei, Qingqing Yi, Lijuan Shen, Boshun Wan, Yueyu Chen, Qing Chang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Gastrointestinal symptoms occur in approximately 50% of patients with systemic lupus erythematous with low specificity. Although it is well established that colon cancer is one of the many gastrointestinal manifestations associated with systemic lupus erythematous, the diagnosis and treatment remains complex due to adrenal insufficiency symptoms.

Case presentation

A 43-year-old Chinese woman with a five-year history of systemic lupus erythematous was diagnosed with colon cancer based on imaging test. A radical bowel resection was performed successfully. To avoid serious complications during surgery, prednisone was replaced with methylprednisolone therefore avoiding adrenal insufficiency. The patient was subsequently treated with mFOLFOX6 chemotherapy and recovered well.

Conclusion

There is a lack of reports for treatment of colon cancer in patients with systemic lupus erythematous. This report provides an effective way to diagnose colon cancer in patients with systemic lupus erythematous and illustrates a successful therapy strategy for this complex medical condition.
Literature
1.
Brewer BN, Kamen DL. Gastrointestinal and hepatic disease in systemic lupus erythematosus. Rheum Dis Clin N Am. 2018;44(1):165–75.CrossRef
2.
Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol. 2011;45(5):436–41.CrossRefPubMed
3.
Lewis RB, Castor CW, Knisley RE, Bole GG. Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1976;19(6):1256–60.CrossRefPubMed
4.
Lopez Dupla M, Khamashta M, Pintado Garcia V, Lavilla Uriol P, Valencia Ortega E, Gil Aguado A. Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients. Lupus. 1993;2(6):377–80.CrossRefPubMed
5.
Rahner N, Höefler G, Högenauer C, Lackner C, Steinke V, Sengteller M, Friedl W, Aretz S, Propping P, Mangold E, Walldorf C. Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus. Am J Med Genet A. 2008;146A(10):1314–9.CrossRefPubMed
6.
Kijima T, Kanekiyo S, Nakasuga C, Inoue Y, Shindo Y, Tsutsui M, Yoshino S, Kubo M, Yano M, Bimoto M, Kanda T, Hazama S, Oka M. A case report of a patient with overlap syndrome systemic lupus erythematosus (SLE) and polymyositis (PM) whose condition improved following treatment for coexisting descending colon cancer. Gan To Kagaku Ryoho. 2013;40(12):1936–8.PubMed
7.
Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, Bijedic N, Bjelogrlic I, Gogov B, Mehmedovic A. Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med Arch. 2013;67(6):397–401.CrossRefPubMedCentralPubMed
8.
Mukkai Krishnamurty D, Wise PE. Importance of surgical margins in rectal cancer. J Surg Oncol. 2016;113(3):323–32.CrossRefPubMed
Metadata
Title
Treatment of colon cancer in a patient with systemic lupus erythematosus: a case report
Authors
Junfeng Shi
Jianquan Fei
Qingqing Yi
Lijuan Shen
Boshun Wan
Yueyu Chen
Qing Chang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4864-x

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

TRH site-specific methylation in oral and oropharyngeal squamous cell carcinoma

Research article

The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients

Research article

Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer

Research article

Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

Research article

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma

Study protocol

Comparison of implementation strategies to influence adherence to the clinical pathway for screening, assessment and management of anxiety and depression in adult cancer patients (ADAPT CP): study protocol of a cluster randomised controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits